Washington, D.C.
The Speak Foundation, in collaboration with CureLGMD2i
Foundation and the LGMD2D Foundation, are pleased to announce that we will be holding ...
Washington, D.C.
United States
Lace up your favorite sneakers and get moving! Join us for our first annual virtual 5K event, Hope in Motion: LGMD2D Awareness 5K. Whether y...
United States
International
Limb-Girdle Muscular Dystrophy Awareness Day is an annual collaborative effort to globally raise awareness of individuals living with limb-g...
International
Orlando, FL
SAVE THE DATE! The next International LGMD Conference is being held from Friday, July 18 - Sunday, July 20, 2025, in Orlando, FL, with an o...
Orlando, FL
On February 8, 2024, The Speak Foundation convened several academic medical experts, senior leaders from the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), highly experienced drug developers, and other specialists that all sought to answer important questions on how to drive momentum to fulfill the unmet, yet critical need of the patient community to accelerate drug development for LGMDs. The meeting focused on six LGMD subtypes: 2A/R1, 2B/R2, 2C/R5, 2D/R3, 2E/R4, and 2I/R9.
The LGMD Scientific Workshop provided scientific and medical experts, regulators, patients, and drug development stakeholders the opportunity to explore innovative drug development approaches and clinical trial designs targeting the causal pathways and appropriate clinical and surrogate endpoints tailored for each subtype.
The International LGMD Conference is an informative event where LGMD patients and caregivers can hear sessions about updates on the latest research and new information from the pharmaceutical industry by the world's leading biotechs. Grasp LGMD researchers, also the world's best on LGMD, were at this event to give firsthand information on new clinical trials.
The LGMD2D Foundation was a proud Advocacy Sponsor of the
2023 conference.
The first externally led patient-focused drug development (EL-PFDD) meeting for LGMD was held on September 23,2022. This monumental event gave individuals diagnosed with limb-girdle muscular dystrophy types 2A, 2C, 2D, 2E, 2F, and 2I an opportunity to share with the FDA and other stakeholders about the experiences and challenges of living with LGMD.
The Speak Foundation's magazine created just for the LGMD community. Subscribing is free and confidential.
All proceeds will go to LGMD2D research, awareness & advocacy.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.